STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma

Noriyuki Ito, Masatoshi Eto, Eijiro Nakamura, Atsushi Takahashi, Taiji Tsukamoto, Hiroshi Toma, Hayakazu Nakazawa, Yoshihiko Hirao, Hirotsugu Uemura, Susumu Kagawa, Hiroomi Kanayama, Yoshiaki Nose, Naoko Kinukawa, Tsuyoshi Nakamura, Nobuyoshi Jinnai, Toyokazu Seki, Masanobu Takamatsu, Yoshihiro Masui, Seiji Naito, Osamu Ogawa

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Purpose: To clarify the effect of genetic polymorphisms on the response to interferon alfa (IFN-α) for metastatic renal cell carcinoma (MRCC), and to find a reliable molecular marker to select those patients with MRCC who would benefit from IFN-α immunotherapy. Patients and Methods: We carried out an association study in which 463 single nucleotide polymorphisms (SNPs) in 33 candidate genes were genotyped in 75 Japanese patients who had received IFN-α for MRCC. Results: After adjusting for lung metastasis, stepwise logistic regression analysis revealed that the SNPs in signal transducer and activator 3 (STAT3) were most significantly associated with better response to IFN-α. Linkage disequilibrium mapping revealed that the SNP in the 5′ region of STAT3, rs4796793, was the most significant predictor of IFN-α response (odds ratio [OR] = 2.73; 95% CI, 1.38 to 5.78). The highest OR was shown in the CC genotype at rs4796793 compared to the GG + GC genotypes (OR = 8.38, 95% CI, 1.63 to 42.96). Genotype-dependent expressions of STAT3 in B lymphocyte cell lines and the enhanced growth inhibitory effects of IFN-α by STAT3 suppression in an RCC cell line supported the results of the present association study. Conclusion: The present study suggested that the STAT3 polymorphism is a useful diagnostic marker to predict the response to IFN-α therapy in patients with MRCC. An efficient response marker for IFN-α needs to be utilized to establish individual optimal treatment strategies, even when newer drug therapies are used as first line treatments for MRCC.

Original languageEnglish
Pages (from-to)2785-2791
Number of pages7
JournalJournal of Clinical Oncology
Volume25
Issue number19
DOIs
Publication statusPublished - Jul 1 2007
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Ito, N., Eto, M., Nakamura, E., Takahashi, A., Tsukamoto, T., Toma, H., Nakazawa, H., Hirao, Y., Uemura, H., Kagawa, S., Kanayama, H., Nose, Y., Kinukawa, N., Nakamura, T., Jinnai, N., Seki, T., Takamatsu, M., Masui, Y., Naito, S., & Ogawa, O. (2007). STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 25(19), 2785-2791. https://doi.org/10.1200/JCO.2006.09.8897